The evolution of cyclin dependent kinase inhibitors in the treatment of cancer. Issue 10 (3rd October 2021)

• Record Type: Journal Article
• Authors: Jhaveri, Komal; Burris 3rd, Howard A; Yap, Timothy A; Hamilton, Erika; Rugo, Hope S; Goldman, Jonathan W; Dann, Stephen; Liu, Feng; Wong, Gilbert Y; Krupka, Heike; Shapiro, Geoffrey I
• Is Part Of: Expert review of anticancer therapy. Volume 21:Issue 10(2021)
• Page Start: 1105
• Page End: 1124
• Publication Date: 2021-10-03
• Subjects: Breast -- biomarkers -- cancer -- cell cycle -- cyclin dependent kinase inhibitor -- oncology -- resistance; Cancer -- Treatment -- Periodicals; 616.99406
• DOI: 10.1080/14737140.2021.1944109
• Languages: English
• ISSNs: 1473-7140

Abstract

ABSTRACT: Introduction: The cell cycle cyclin-dependent kinases (CDKs) play a critical role in controlling the transition between cell cycle phases, as well as cellular transcription. Aberrant CDK activation is common in cancer, and deregulation of the cell cycle a key hallmark of cancer. Although CDK4/6 inhibitors are now a standard-of-care option for first- and second-line HR+/HER2- metastatic breast cancer, resistance inevitably limits their clinical benefit. Areas covered: Early pan-CDK inhibitors targeted the cell cycle and RNA polymerase II phosphorylation, but were complicated by toxicity, providing a rationale and need for the development of selective CDK inhibitors. In this review, we highlight selected recent literature to provide a narrative review summarizing the current CDK inhibitor therapeutic landscape. We detail the challenges associated with targeting CDKs for the treatment of breast and other cancers and review emerging biomarkers that may aid response prediction. We also discuss the risk-benefit ratio for CDK therapy and explore promising combination approaches. Expert opinion: Although CDK inhibitors may stem the proliferation of cancer cells, resistance remains an issue, and currently there are limited biomarkers to predict response to therapy. Ongoing research investigating CDK inhibitors in cancer is of paramount importance to define appropriate and effective treatment regimens.